about
MiRNAs and miRNA Polymorphisms Modify Drug ResponseClerosterol from vinegar-baked radix bupleuri modifies drug transport.Chemosensitizing indomethacin-conjugated dextran-based micelles for effective delivery of paclitaxel in resistant breast cancer therapy.3-bromopyruvate enhanced daunorubicin-induced cytotoxicity involved in monocarboxylate transporter 1 in breast cancer cellsPOLYMERIC BIOMATERIALS AND NANOMEDICINES.Semi-synthetic ocotillol analogues as selective ABCB1-mediated drug resistance reversal agents.Efficacy of traditional Chinese medicine in treating cancer.Evaluation of Near Infrared Dyes as Markers of P-Glycoprotein Activity in TumorsRevisiting the role of nanoparticles as modulators of drug resistance and metabolism in cancer.Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib.Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells.Selective GPR55 antagonism reduces chemoresistance in cancer cells.Gene expression profiling of tumor-initiating stem cells from mouse Krebs-2 carcinoma using a novel marker of poorly differentiated cellsThe therapeutic potential of targeting ABC transporters to combat multi-drug resistance.Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications.Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters.Establishment and characterization of arsenic trioxide resistant KB/ATO cells.Doxorubicin-loaded redox-responsive micelles based on dextran and indomethacin for resistant breast cancer.Tea nanoparticle, a safe and biocompatible nanocarrier, greatly potentiates the anticancer activity of doxorubicin.Effect of Y6, an epigallocatechin gallate derivative, on reversing doxorubicin drug resistance in human hepatocellular carcinoma cells.Ubenimex suppresses Pim-3 kinase expression by targeting CD13 to reverse MDR in HCC cells.Multidrug resistance-associated protein 4 is a bile transporter of Clonorchis sinensis simulated by in silico docking.Function of insulin-like growth factor 1 receptor in cancer resistance to chemotherapy.Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N-Methyl-d-aspartate (NMDA) Receptor Antagonist.Selective ATP-Binding Cassette Subfamily C Gene Expression and Proinflammatory Mediators Released by BEAS-2B after PM2.5, Budesonide, and Cotreated Exposures.Augmenter of liver regeneration potentiates doxorubicin anticancer efficacy by reducing the expression of ABCB1 and ABCG2 in hepatocellular carcinoma.GSK1904529A, a Potent IGF-IR Inhibitor, Reverses MRP1-Mediated Multidrug Resistance.Molecular and structural characteristics of multidrug resistance-associated protein 7 in Chinese liver fluke Clonorchis sinensis.Signaling lymphocytic activation molecules Slam and cancers: friends or foes?ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward?Drug Transport at the Brain and Endothelial Dysfunction in Preeclampsia: Implications and Perspectives
P2860
Q28079075-3D482241-59C7-440F-9DF9-0F261A48A547Q33591530-F66226EB-BEB3-4108-9DF3-90A9D3864E79Q33883851-A2A4956C-B198-45D3-A948-6040999A999BQ34503166-AD98EA9A-97F3-4627-AB97-E8A06C9769F6Q36376467-1CED303E-902F-4BCE-83FF-4DE8D51B963BQ36414444-2E039403-1DFC-4B08-A0FD-9FE8AAECC1F0Q36502153-87F06833-9AE3-444B-901D-B91072024C8BQ37413413-5959FC43-B7E5-44AF-BB04-E1C9D201473FQ38707907-3941FEAF-73BB-471C-9923-526C79B2D156Q38718947-4D4FA825-3B14-4C38-9B5E-36D96F4FB431Q38744729-BD8FE274-48B4-427E-A43D-9B34647CF0FCQ38757793-9B42D847-8D3C-4C27-B48A-93C70D36D7BEQ39056377-44A57AA1-DEBD-4FC5-A637-0F14AACBCD7EQ39196784-BD2F0F4B-C0FF-44D6-996F-47F19DC65FFEQ39400621-78D1874B-B6BB-45F4-8BCA-23663DF46822Q41168634-AB4299E0-CF43-4C6D-B01C-F824FC90ED8AQ41229604-1D6DE0E7-4937-4F4E-BA3D-EDDB7880BCBBQ41545913-56DA9DD3-97C8-4EB7-801A-2EFECE2F99E9Q42052611-9F1A140E-716F-4446-9CC6-3B2C93535E25Q42118943-8C739878-8630-4A97-B4F2-AE3A1A74CA35Q42700754-5695D064-7532-4C9D-AAB9-AF56E8477052Q45418018-9332FF0D-2A8F-4A4F-A3E7-7F019385ACA1Q47095382-E523A5E0-E9AB-4A0C-98D9-005F0FC4B3DCQ47330693-6A986D67-8CD4-48DD-A692-9046C0BC3F41Q47813843-49A9C040-12B0-4D76-9CB0-F76CBD0B76BFQ47927666-E7771B72-BD24-41AB-BF17-EE7EF6E465F5Q48156853-64C98CF9-2F6B-44CF-B8BE-40FAE6970299Q51213476-149EBC5D-A3BC-40D6-9AA0-4563295C8071Q52584346-30128C70-FD07-4407-9BAC-F83F2154092CQ58798114-4A4E0AA8-90F2-4962-A234-A68E7B436AB4Q59136492-35634222-0AB4-4231-B380-23DA404B5AFB
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Multidrug Resistance Proteins (MRPs) and Cancer Therapy
@ast
Multidrug Resistance Proteins (MRPs) and Cancer Therapy
@en
Multidrug Resistance Proteins (MRPs) and Cancer Therapy
@nl
type
label
Multidrug Resistance Proteins (MRPs) and Cancer Therapy
@ast
Multidrug Resistance Proteins (MRPs) and Cancer Therapy
@en
Multidrug Resistance Proteins (MRPs) and Cancer Therapy
@nl
prefLabel
Multidrug Resistance Proteins (MRPs) and Cancer Therapy
@ast
Multidrug Resistance Proteins (MRPs) and Cancer Therapy
@en
Multidrug Resistance Proteins (MRPs) and Cancer Therapy
@nl
P2093
P2860
P3181
P1433
P1476
Multidrug Resistance Proteins (MRPs) and Cancer Therapy
@en
P2093
Pranav Gupta
Yi-Jun Wang
Yun-Kai Zhang
Zhe-Sheng Chen
P2860
P2888
P304
P3181
P356
10.1208/S12248-015-9757-1
P407
P577
2015-07-01T00:00:00Z
P5875
P6179
1022272114